Staphylococcus Aureus clinical trials at UC Davis
1 research study open to eligible people
A Study of the Combination of Experimental AR-301 and Antibiotics for Staphylococcus Aureus Ventilator-Associated Pneumonia
open to eligible people ages 18 years and up
AR-301 is being evaluated as an adjunctive treatment of ventilator-associated pneumonia (VAP) due to Staphylococcus aureus (S. aureus) in combination with standard of care (SOC) antibiotic therapy in patients with confirmed S. aureus infection.
Sacramento, California and other locations